Viome Life Sciences, Inc.
PrivateLast Round
Series D
Sep 10, 2024
Est. Valuation
$339M
Total Funding Raised
$337.5M
Company Overview
Viome Life Sciences, Inc. is a biotechnology company that provides at-home health tests analyzing microbial and human gene expressions to offer personalized nutrition and supplement recommendations.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, D2C Brands, Subscription Commerce
Business Model
B2C
Customer Profile
Subscription SaaS, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Viome Life Sciences, Inc. Comparables
Compare Viome Life Sciences, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ZOE | 87% | |
| Ombre | 83% | |
| Elo Health | 79% | |
Viome Life Sciences, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 10, 2024 | ||||
| Series C Extension | Aug 18, 2023 | ||||
| Series C | Oct 18, 2022 | ||||
| Convertible Debt | Nov 10, 2021 | ||||
| Debt | Feb 10, 2021 | ||||
Series B | Nov 27, 2019 |
Viome Life Sciences, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ocgrow Ventures | Convertible Debt, Series C |
| Ezaki Glico Co., Ltd. | Convertible Debt, Series B, Series C |
| Khosla Ventures | Convertible Debt, Series B, Series D, Series B Extension, Series C, Series A, Series C Extension |
| Bold Capital Group | Convertible Debt, Series B, Series C |
| WRG Ventures | Series D, Series C Extension |
| WestRiver Group | Convertible Debt, Series C |
| BOLD Capital Partners | Series A, Series B, Series D, Series C Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 18, 2025
Integration to leverage secure and scalable infrastructure services.
- Apr 14, 2025
Launched AI-powered RNA diagnostics for precision nutrition.
Viome Life Sciences, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Viome Life Sciences, Inc.'s valuation, stock price, and market status.